COVID-19 Continues To Hinder Teva Opioid Settlement – Although Deal Is ‘Close’
Teva ‘Optimistic’ About Proposed Framework; But ‘Pessimistic’ About Timing
Executive Summary
Uncertainty over resolving opioids litigation led Teva to write down the value of its goodwill by more than $4bn in 2020. Management has provided the latest update on getting a deal over the line and removing a significant legal overhang.
You may also be interested in...
Teva’s Legal Woes Lead To $4.6bn Hit
Teva reported a substantial loss in the third quarter after registering a goodwill impairment of $4.6bn, largely linked to legal uncertainties as the firm continues to grapple with price-fixing litigation in the US and its pending opioids settlement.
Teva Seeks Global Resolution Of Opioid Litigation
Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework.
Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: